Head-to-head comparison of the new calcimimetic agent evocalcet with cinacalcet in Japanese hemodialysis patients with secondary hyperparathyroidism-Reference-Cited by-同舟云学术

Head-to-head comparison of the new calcimimetic agent evocalcet with cinacalcet in Japanese hemodialysis patients with secondary hyperparathyroidism

Published:2018-10 Issue:4 Volume:94 Page:818-825
ISSN:0085-2538
Container-title:Kidney International
language:en
Short-container-title:Kidney International

Author:

Fukagawa Masafumi,Shimazaki Ryutaro,Akizawa Tadao

Publisher

Elsevier BV

Subject

Nephrology

Reference18 articles.

1. Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options;Cunningham;Clin J Am Soc Nephrol,2011

2. Diseases of the parathyroid gland in chronic kidney disease;Komaba;Clin Exp Nephrol,2011

3. Executive summary of the 2017 KDIGO Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD) Guideline Update: what's changed and why it matters;Ketteler;Kidney Int,2017

4. Decreases in PTH in Japanese hemodialysis patients with secondary hyperparathyroidism: associations with changing practice patterns;Akizawa;Clin J Am Soc Nephrol,2011

5. Calcimimetic agents in the management of secondary hyperparathyroidism among patients with end-stage renal disease; a review article;Beladi-Mousavi;J Parathyr Dis,2015

Cited by 71 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effects of active vitamin D analogs and calcimimetic agents on PTH and bone mineral biomarkers in hemodialysis patients with SHPT: a network meta-analysis;European Journal of Clinical Pharmacology;2024-07-13

2. Discovery and pharmacological characterization of nanobodies acting as potent positive allosteric modulators of the calcium-sensing receptor;2024-07-08

3. Lower Parathyroid Hormone Levels are Associated With Reduced Fracture Risk in Japanese Patients on Hemodialysis;Kidney International Reports;2024-07

4. Current therapeutic approach of chronic kidney disease‐mineral and bone disorder;Therapeutic Apheresis and Dialysis;2024-06-19

5. Secondary hyperparathyroidism in chronic kidney disease: pathophysiology, current treatments and investigational drugs;Expert Opinion on Investigational Drugs;2024-06-19